



## Employee Stock Issue

*Charenton-le-Pont France (November 26, 2013 - 6:00 p.m.)* - At the Extraordinary Shareholders' Meeting of May 16, 2013, Essilor International's Board of Directors was given a 21-month authorization to issue shares to members of Essilor employee stock ownership plans (11<sup>th</sup> resolution). The maximum number of common shares authorized for issuance was set at 3,209,647, representing no more than 1.5% of capital stock.

At its meeting on November 25, 2013, the Board of Directors decided to use this authorization to issue up to 440,000 common shares for subscription by members of the Essilor / BBGR / Novisia / BNL Eurolens / Delamare Sovra and OMI employee stock ownership plans.

The new shares will carry rights as from January 1<sup>st</sup>, 2013. They will be offered at a price of €61.83 per share, corresponding to the average of the opening prices quoted over the last twenty trading days preceding the Board's November 25, 2013 decision to issue the shares, less a 20% discount.

Employees may purchase the shares through two funds. These funds have been given a specific value since January 1<sup>st</sup>, 2013, the start date of the subscription period. The closing date of the subscription period is December 8, 2013. The actual number of shares issued will be announced on December 20, 2013 and the Company will then apply for the new shares (par value: €0.18) to be listed on NYSE Euronext.

The Company's capital stock amounts to €38,515,769.10, represented by 213,976,495 shares.

### **About Essilor**

*The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its corporate mission is to enable everyone around the world to access lenses that meet his or her unique vision requirements. To support this mission, the Company allocates more than €150 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Essilor's flagship brands are Varilux<sup>®</sup>, Crizal<sup>®</sup>, Definity<sup>®</sup>, Xperio<sup>®</sup>, Optifog<sup>™</sup> and Foster Grant<sup>®</sup>. It also develops and markets equipment, instruments and services for eyecare professionals.*

*Essilor reported consolidated revenue of approximately €5 billion in 2012 and employs around 50,700 people. It operates in some 100 countries with 22 plants, more than 400 prescription laboratories and edging facilities, as well as several research and development centers around the world.*

*For more information, please visit [www.essilor.com](http://www.essilor.com).*

*The Essilor share trades on the NYSE Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices.*

*Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.*

-----

**Investor Relations and Financial Communications**

Phone: +33 (0)1 49 77 42 16